Cite
HARVARD Citation
Paz-Ares, L. et al. (2019). Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 394 (10212), pp. 1929-1939. [Online].